Stock Events

Barinthus Biotherapeutics. 

$2.7
2
+$0.1+3.85% Thursday 20:59

Statistics

Day High
-
Day Low
-
52W High
5.1
52W Low
1.64
Volume
10,607
Avg. Volume
14,582
Mkt Cap
104.13M
P/E Ratio
-1.34
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MarExpected
Q2 2023
Q3 2023
Next
-0.62
-0.59
-0.56
-0.53
Expected EPS
-0.59
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRNS. It's not an investment recommendation.

Analyst Ratings

15$Average Price Target
The highest estimate is $15.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Show more...
CEO
Employees
49
Country
US
ISIN
US91864C1071
WKN
000A3CN5Q

Listings